<?xml version='1.0' encoding='utf-8'?>
<document id="17332143"><sentence text="Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study."><entity charOffset="224-236" id="DDI-PubMed.17332143.s1.e0" text="methotrexate" /></sentence><sentence text="DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] is a potent human tumor necrosis factor alpha-converting enzyme inhibitor with potential therapeutic implications for rheumatoid arthritis" /><sentence text=" Methotrexate (MTX), a drug for the treatment of rheumatoid arthritis, is eliminated primarily unchanged via renal and biliary excretion in humans as well as in rats and dogs"><entity charOffset="1-13" id="DDI-PubMed.17332143.s3.e0" text="Methotrexate" /><entity charOffset="15-18" id="DDI-PubMed.17332143.s3.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.17332143.s3.e0" e2="DDI-PubMed.17332143.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17332143.s3.e0" e2="DDI-PubMed.17332143.s3.e1" /></sentence><sentence text=" The objective of the present study was to investigate the potential effect of DPC 333 on the disposition of MTX"><entity charOffset="109-111" id="DDI-PubMed.17332143.s4.e0" text="MTX" /></sentence><sentence text=" In dogs, DPC 333 administered orally at 1" /><sentence text="7 mg/kg 15 min before the intravenous administration of [14C]MTX (0"><entity charOffset="56-64" id="DDI-PubMed.17332143.s6.e0" text="[14C]MTX" /><entity charOffset="61-68" id="DDI-PubMed.17332143.s6.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.17332143.s6.e0" e2="DDI-PubMed.17332143.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17332143.s6.e0" e2="DDI-PubMed.17332143.s6.e1" /></sentence><sentence text="5 mg/kg) did not alter the plasma concentration-time profile of MTX; however, the total amount of radioactivity excreted in urine increased from 58"><entity charOffset="64-67" id="DDI-PubMed.17332143.s7.e0" text="MTX" /></sentence><sentence text="7% to 92" /><sentence text="2% of the dose, and the renal clearance increased from 1" /><sentence text="8 ml/min/kg to 2" /><sentence text="9 ml/min/kg, suggesting a decrease in MTX disposition via biliary excretion"><entity charOffset="38-40" id="DDI-PubMed.17332143.s11.e0" text="MTX" /></sentence><sentence text=" The biliary excretion of MTX was investigated in isolated perfused livers prepared from wild-type and TR(-) [multidrug resistance-associated protein 2 (Mrp2)-deficient] Wistar rats in the absence and presence of DPC 333"><entity charOffset="26-28" id="DDI-PubMed.17332143.s12.e0" text="MTX" /></sentence><sentence text=" Mrp2-mediated biliary excretion of MTX was confirmed with 95"><entity charOffset="36-38" id="DDI-PubMed.17332143.s13.e0" text="MTX" /></sentence><sentence text="8% and 5" /><sentence text="1% of MTX recovered in the bile of wild-type and TR(-) Wistar rats, respectively"><entity charOffset="6-9" id="DDI-PubMed.17332143.s15.e0" text="MTX" /></sentence><sentence text=" DPC 333 at an initial perfusate concentration of 50 microM completely blocked the biliary excretion of MTX, but not the clearance from perfusate, in both wild-type and TR(-) rats"><entity charOffset="104-106" id="DDI-PubMed.17332143.s16.e0" text="MTX" /></sentence><sentence text=" These results suggest that the enhanced renal elimination of MTX may be due to the potent inhibition of biliary excretion and active renal reabsorption by DPC 333 and/or its metabolites"><entity charOffset="62-65" id="DDI-PubMed.17332143.s17.e0" text="MTX" /></sentence><sentence text="" /></document>